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E D I TO R I A L

Genome Medicine: past, present and future
Charles Auffray1*, Timothy Caulfield2*, Muin J Khoury3*, James R Lupski4,5*, Matthias Schwab6,7* and Timothy Veenstra8*

The field of genomic medicine continues to expand,
driven by the efforts of numerous researchers around the
world. To celebrate Genome Medicine’s 2nd anniversary,
we asked our Section Editors what they felt were the
most exciting breakthroughs in research in the past
2 years and what the future of genomic medicine might
hold.

Transformational effect of systems medicine
Since we discussed systems medicine as the future of
medical genomics and healthcare in the inaugural issue
of Genome Medicine [1], the field has witnessed transformational changes that have brought the prospect and
promises of personalized medicine closer to reality. The
exponential increase in DNA sequencing capabilities,
together with the rapidly declining associated costs, has
made whole-genome sequencing accessible to small
laboratories, and will soon transform it into a low cost
analytical assay. These advances have enabled the emergence of medical systems genetics studies, an approach in
which the genetic determinants of diseases are investigated through sequencing of the complete genome of
family relatives. For example, sequencing and analysis of
the genomes of two siblings and their parents made
possible the direct measurement of the inter-generational
mutation rate and identified genes potentially associated
with two Mendelian disorders [2]; the gene causing one
of these disorders was precisely identified through further
exome sequencing in additional diseased patients [3].
Another telling example of both the power and current
limitations of the next-generation sequencing approaches
is their application to the characterization of the genome,
epigenome and transcriptome of monozygotic twins
discordant for multiple sclerosis, which failed to uncover
significant differences associated with the disease [4].
With several thousand genomes now being completed,
and tens of thousands anticipated in the coming year, the
limitation is already to a large extent, and will increasingly
be, on the side of data analysis, as the collection, storage
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and analysis of the large datasets generated requires the
combined expertise of a wide variety of scientists,
engineers and physicians [5]. Fortunately, the software,
databases and computing power required for these
community efforts are now becoming available through
computer grids and cloud computing infrastructures,
offering an affordable alternative for genome and translational bioinformatics [6,7]. Combined together, genome
sequencing and cloud computing will contribute to
bridging the gap between systems biology and medicine
by opening the way to the precise and low cost assays that
are necessary for systems medicine to become a practical
alternative to traditional reactive medicine [8].
Charles Auffray, Section Editor,
Systems medicine and informatics

The public perception challenge
Public perception research has long been a big part of the
ethical, legal and social issues (ELSI) research agenda.
Over the past decades a wide range of methods have been
deployed to tease out how the public (whatever that
might be) feels about everything from gene patents to
genetic privacy to the utility of direct-to-consumer testing services. However, understanding public perceptions
has never been more important than it is now. Genomic
research requires even more research participants,
through such initiatives as large population biobanking
studies. And the clinical value of many proposed genomic
interventions depends on a public response to genebased risk information (such as the promotion of healthy
lifestyle changes). Understanding how the public views
and is likely to respond to genetic information will have
an impact on both the nature of research that can be
done and whether we will derive social benefit from that
research. Recent public perception research has demonstrated that the challenges in both of these areas could be
profound. For example, a study that included 16 focus
groups and a survey of over 4,000 individuals concluded
that the public wants ongoing control over their genetic
samples that have been donated for research [9]. Subsequent studies have come to similar results [10]. People
want ‘control.’ They want to consent. But can we give
meaning to this public desire and still carry out big
genomic studies? The research on how people respond to
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genomic information is also illuminating and somewhat
deflating, at least from a public health perspective. The
emerging data, wonderfully summarized in a recent
Cochrane Collaboration review [11], highlights that the
public response to genetic risk information seems likely
to be rather muted [12]. Given this reality, at least one
aspect of the long promised benefits of genomicsinformed personalized medicine - that is, the promotion
of individualized preventive health strategies - may not
pan out as expected. What is probably needed is both a
more realistic appraisal of how genetic information will
assist approaches to public health and more research into
the ways in which genetic information can supplement, if
at all, existing disease risk information.
Timothy Caulfield, Section Editor,
Social, ethical and legal issues in genomic medicine

The translational gap in genomic medicine
Rapid advances in genomics and related technologies are
promising a new era of personalized healthcare and
disease prevention, including new drugs, diagnostic and
screening tests based on individual genetic makeup and
disease biomarkers. Scientists predict that the age of
personalized health care has arrived. Nevertheless, the
gap is still wide between new discoveries and their
clinical validity and utility in practice [13]. The expansion
of direct-to-consumer marketing of personal genome
profiles for risk assessment and disease prevention illus
trates the premature deployment of this technology
without the appropriate evidence base to support their
use in practice [14]. If the promise of genomics is to be
fulfilled, we must use scientific methods to document
how such technologies can improve health and prevent
disease in practice. Dealing with the genomics evidence
gap will require two key and interrelated science and
policy areas, which are crucial to accelerating the appro
priate translation of genomics into clinical practice. The
first is to develop a multidisciplinary translation research
agenda, including more clinical and population-based
research, in the life cycle of research from the bench to
improved population health outcomes [15,16], and the
second is to develop a stakeholder collaboration to effect
evidence-based translation. Translation research is
necessary, but not sufficient, to move specific genomic
applications from research into practice. Actual trans
lation is even more complicated. Different forces can
accelerate or impede the translation process, such as
private investments in research and development, policy
and legal frameworks, oversight and regulation, product
marketing, coverage and reimbursements, consumer
advocacy, provider awareness, access, and health services
development and implementation [17,18].
Muin Khoury, Section Editor,
Genomic epidemiology and public health genomics
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Genome Medicine and personal genomics
In order for the discipline of genomic medicine to fulfill
its maximum potential and utility in the clinic, it is
necessary to be able to characterize all forms of genetic
variation in an individual patient’s genome. This includes
single or simple nucleotide variation (SNV) and copy
number variation (CNV). Personal genome sequencing is
becoming a reality. The complete nucleotide sequence of
James Dewey Watson, 55 years after his discovery of
DNA and two decades after he led the human genome
project, provided tremendous insights into personal
genomes. It was the first human genome sequenced by
next generation sequencing [19] and revealed extensive
variation: greater than 3 million SNV differences in
comparison with the reference haploid human genome
sequence and a high frequency of small sized CNVs (less
than 1 kb) that were beyond the detection limits of array
comparative genomic hybridization. Another major find
ing was the amount of Alu repetitive element polymorph
isms - indels (insertions or deletions) representing
dimorphisms of Alu at a particular locus. Thus, for each
personal genome the amount of structural variation related
to the position of repetitive elements could be immense.
The remarkable extent of genome structural variation in
populations was further revealed by Conrad et al. [20].
The next important step in personal genomics was to
use whole-genome sequence to associate specific varia
tion with clinical disease phenotypes, and thus identify
medically actionable variation from the myriad of benign
polymorphic variations; that is, detect signal from noise.
Whole-genome sequencing (WGS) was used to identify
the cause of Charcot-Marie-Tooth neuropathy. Surprisingly,
this work also provided insights into genetic variation
underlying common complex traits such as carpal tunnel
syndrome [21]. Whole exome sequencing (WES) has
also now been used to find the medically actionable
alleles in defined clinical Mendelian phenotypes for
which the causative genes were unknown (for example,
[3,22-24]), and to make a definitive diagnosis for a
patient with a complex trait [25]. Further exome
sequencing work recently documented that new
mutations may contribute in a significant way to
common traits such as mental retardation and
intellectual disability [26]. This latter study emphasizes
the importance of personal genomics for assessing not
only inherited variation but also de novo events.
However, we must not lose sight of the challenges!
Exome sequencing provides essentially no information
about structural variation and CNV. Whole-genome
sequencing can provide structural variation information,
but it is not obvious to what extent short read sequences
can capture CNV, such as those of only a few hundred
base pairs that may delete or duplicate single exons [27]
or delineate complex rearrangements, given the
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information filtering step required in matching short
reads to a haploid human reference genome. Whether or
not WES or WGS will discern repeat expansion, a highly
significant form of pathology-associated genetic
variation, also remains to be demonstrated. Nevertheless,
from the insights already provided, it is clear that the
information that can be gleaned from personal genome
sequencing will probably be so compelling that clinicians
will be motivated to rapidly adapt it into clinical practice.
James R Lupski, Section Editor,
Molecular genetics, genomics and epigenetics of disease

The paradigm-shift of personalized medicine
The modern concept of personalized medicine is
stimulated by the idea that genomic medicine may help
to prevent and/or treat diseases by the use of the
individual genetic information of the host, tumor and/or
other biological organisms (such as bacteria). Pharmaco
genomics, a distinct discipline within the field of
personalized medicine, includes the study of the
influence of genetic variation on drug response, but also
comprises the genome-wide and multi-factorial exten
sion. Thus, in the modern conception of personalized
medicine, the tools that are provided to the physician are
hopefully more precise, considering not just the obvious,
such as a malign tumor by computer tomography, but the
individual genetic make-up of the patient. There are
several examples in which a profile of a patient’s genetic
variation is used to guide the selection of drugs or
treatment processes, leading to a more successful out
come from the medical treatment [28]. The question is
no longer what if this could happen in clinical practice,
but when. Consideration of new ‘omics-based biomarkers
for patient stratification should by no means exclude the
use of traditional biomarkers, such as a patient’s age,
body composition, physical examination findings, blood
pressure, and so on, for diagnosis of disease and choice of
prevention or treatment. However, personalized treat
ment needs to combine clinical assessment and disease
diagnostic tests with treatment-related (genetic) tests. In
addition to biomarkers predicting the efficacy and, if
possible, effectiveness of a treatment, sufficient attention
must also be given to the use of biomarkers for predicting
drug safety. Considerable research activities in biomarker
discovery and validation are ongoing, but little is being
done to bring this information into clinical practice [29].
The cost of sequencing the human genome falls and
whole-genome sequencing is already occurring, but data
interpretation requires expertise not only related to the
genetics of disease, but also related to pharmacological
principles. Continuing Medical Education courses on
personalized medicine, particularly with focus on
genomic issues, need to be made available to bring
physicians to the latest technological developments. To
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this end there is still a substantial need to demonstrate
the potential added value that personalized genomicbased approaches bring, in particular the added value of
patient stratification in view of improved effectiveness
and/or reduction of adverse side effects.
Matthias Schwab, Section Editor,
Personalized medicine and therapeutics

From sensitive technologies to clinical action
Undoubtedly the greatest advances in translational
medicine over the past decade have been in the area of
genetics. The advent of next-generation sequencing tech
nologies have made genome-wide association studies, the
identification of large numbers of single nucleotide
polymorphisms and copy number variants that influence
disease possible. In the post-genomic era, the hope is that
advances in proteomic measurements can mimic those
made in genetics. Although progress has not been as
dramatic, technologies for protein measurements are
making important strides in translational medicine. If
proteomic technologies are to have an impact on
translational medicine, however, they must be adaptable
to analyzing clinic samples. This requirement means
analyzing small volumes of biofluids and thin tissue
sections, both fresh frozen and formalin-fixed. One of the
most important developments to achieving this goal is
the increasing sensitivity provided by mass spectro
meters. In the past highly sensitive mass spectrometers
were limited to specialized mass spectrometry (MS)
laboratories. Nowadays, instruments that routinely
measure sub-femtomole levels of proteins in complex
biological matrices are being widely used in traditionally
non-MS laboratories. Thousands of proteins can now be
identified from as little as 100 µl of blood [30]. Laser
capture microdissection of approximately 5,000 cells
from thin tissue sections can now provide upwards of
2,500 confident protein identifications [31]. With the
development of methods to extract proteins from
formalin-fixed tissue sections, MS can now analyze a
seemingly inexhaustible source of tissues from countless
tumor types [32]. The sensitivity provided by modern mass
spectrometers leads to greater proteomic coverage for
identifying disease-specific biomarkers and enhancing the
quantitative measurement of specific proteins in clinical
samples. Unfortunately, increased sensitivity compounds
an existing problem specifically in the use of MS for the
discovery of disease-specific biomarkers: turning data into
information. The next big development in post-genomic
medicine will be devising methods or bioinformatic tools
to recognize potentially valuable protein biomarkers in the
complex datasets generated using MS.
Timothy D Veenstra, Section Editor,
Post-genomic advances in medicine
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